Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03758651 · ClinicalTrials.gov registry record
Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 144
- Enrollment target
NCT03758651: Completed study, sponsored by Massachusetts General Hospital.
NCT03758651 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03758651 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 144 participants
- Enrollment target
Study Summary
Williams syndrome (WS) is a rare microdeletion genetic disorder that has a broad phenotype including many endocrine and metabolic abnormalities. Dr. Pober and colleagues at MGH have reported the following findings in adults with WS: abnormal body composition (excess body fat accumulation with a lipedema phenotype), decreased bone mineral density, abnormal glucose tolerance, and reduced lean mass. Despite the high prevalence and potential effect of metabolic abnormalities on the health of persons with WS, their full phenotypic range, potential causal factors (either genetic and/or hormonal) along with their impact on other aspects of health (such as risk of falls and fractures or interaction with emotional behavioral concerns) remain incompletely characterized. The purpose of the current study in a large cohort of subjects with WS is to: collect further information to characterize the timing of onset and distribution of body fat; better characterize hormonal status of WS subjects; and screen for genetic variation using single-nucleotide-polymorphism (SNP) analysis that could elucidate genetic contributors to the lipedema phenotype as well as the other observed metabolic and bone abnormalities.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-09-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03758651
The ClinicalTrials.gov registry entry for NCT03758651 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03758651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03758651 about?
NCT03758651 is a clinical study titled "Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study". Williams syndrome (WS) is a rare microdeletion genetic disorder that has a broad phenotype including many endocrine and metabolic abnormalities. Dr. Pober and colleagues at MGH have reported the following findings in adults with WS: abnormal body composition (excess body fat accumulation with a lipe...
What is the current status of trial NCT03758651?
This trial is currently completed. The enrollment target is 144 participants. The study started on 2018-10-01. Estimated completion is 2023-09-14.
Who is sponsoring clinical trial NCT03758651?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.